Insmed Historical Income Statement
| INSM Stock | USD 73.15 0.66 0.89% |
Historical analysis of Insmed income statement accounts such as Total Revenue of 320.5 M or Gross Profit of 251.6 M can show how well Insmed Inc performed in making a profits. Evaluating Insmed income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Insmed's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Insmed Inc latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Insmed Inc is a good buy for the upcoming year.
Insmed |
About Insmed Income Statement Analysis
Insmed Inc Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Insmed shareholders. The income statement also shows Insmed investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Insmed Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Insmed Inc. It is also known as Insmed overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Income Before Tax
Income Before Tax which can also be referred as pre-tax income is reported on Insmed income statement and is an important metric when analyzing Insmed Inc profitability. Accounting techniques because taxes can be complex, and not perfectly consistent from one company to company, an analyst may use pre-tax income as a more stable measure of profitability.Most accounts from Insmed's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Insmed Inc current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Insmed Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. At this time, Insmed's Cost Of Revenue is very stable compared to the past year. As of the 24th of November 2024, Total Operating Expenses is likely to grow to about 996.7 M, though EBIT is likely to grow to (632.1 M).
Insmed income statement Correlations
Click cells to compare fundamentals
Insmed Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Insmed income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 4.5M | 20.1M | 27.8M | 24.3M | 10.6M | 11.1M | |
| Interest Expense | 27.7M | 29.6M | 40.5M | 26.4M | 76.3M | 80.1M | |
| Total Revenue | 136.5M | 164.4M | 188.5M | 245.4M | 305.2M | 320.5M | |
| Gross Profit | 112.3M | 124.5M | 144.3M | 190.2M | 239.6M | 251.6M | |
| Other Operating Expenses | 371.7M | 429.6M | 556.2M | 723.5M | 1.0B | 1.1B | |
| Operating Income | (235.2M) | (265.2M) | (367.8M) | (478.1M) | (709.6M) | (674.1M) | |
| Ebit | (235.2M) | (270.5M) | (402.9M) | (453.7M) | (665.3M) | (632.1M) | |
| Research Development | 131.7M | 181.2M | 272.7M | 397.5M | 571.0M | 599.6M | |
| Ebitda | (230.8M) | (250.4M) | (375.1M) | (429.4M) | (654.7M) | (622.0M) | |
| Cost Of Revenue | 24.2M | 39.9M | 44.2M | 55.1M | 65.6M | 68.9M | |
| Total Operating Expenses | 347.5M | 389.8M | 512.1M | 668.4M | 949.3M | 996.7M | |
| Net Income | (254.3M) | (294.1M) | (434.7M) | (481.5M) | (749.6M) | (712.1M) | |
| Income Tax Expense | 777K | 1.4M | (1.8M) | 1.4M | 2.6M | 2.7M | |
| Selling General Administrative | 210.8M | 203.6M | 234.3M | 245.0M | 344.5M | 361.7M | |
| Income Before Tax | (253.6M) | (292.7M) | (436.4M) | (480.2M) | (747.0M) | (709.7M) | |
| Total Other Income Expense Net | (18.3M) | (27.5M) | (61.3M) | (2.0M) | (37.4M) | (35.5M) | |
| Net Income Applicable To Common Shares | (254.3M) | (294.1M) | (434.7M) | (481.5M) | (433.4M) | (411.7M) | |
| Net Income From Continuing Ops | (254.3M) | (294.1M) | (434.7M) | (481.5M) | (749.6M) | (712.1M) | |
| Non Operating Income Net Other | 9.4M | 2.1M | (20.8M) | 3.6M | 3.3M | 3.4M | |
| Tax Provision | 777K | 1.4M | (1.8M) | 1.4M | 2.6M | 2.7M | |
| Interest Income | 4.3M | 15.1M | 17.8M | 1.9M | 2.2M | 2.1M | |
| Net Interest Income | (27.7M) | (29.6M) | (40.5M) | (26.4M) | (81.7M) | (77.6M) | |
| Reconciled Depreciation | 10.2M | 14.2M | 14.2M | 10.3M | 10.6M | 10.6M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Insmed Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Insmed. If investors know Insmed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Insmed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.55) | Revenue Per Share 2.206 | Quarterly Revenue Growth 0.182 | Return On Assets (0.26) | Return On Equity (8.91) |
The market value of Insmed Inc is measured differently than its book value, which is the value of Insmed that is recorded on the company's balance sheet. Investors also form their own opinion of Insmed's value that differs from its market value or its book value, called intrinsic value, which is Insmed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Insmed's market value can be influenced by many factors that don't directly affect Insmed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Insmed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Insmed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Insmed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.